T1	p 59 67	myositis
T2	p 85 113	with methotrexate or placebo
T3	p 216 259	44 patients with inclusion body myositis in
T4	i 90 115	methotrexate or placebo .
T5	i 154 182	week oral methotrexate could
T6	i 286 304	placebo-controlled
T7	i 525 537	methotrexate
T8	i 553 560	placebo
T9	i 840 852	methotrexate
T10	i 878 895	oral methotrexate
T11	o 20 40	weakness progression
T12	o 332 389	change of quantitative muscle strength testing sum scores
T13	o 430 486	Quantitative muscle strength testing sum scores declined
T14	o 657 735	in manual muscle testing sum scores , activity scale scores and patients ' own
T15	o 778 818	Serum creatine kinase activity decreased
T16	o 914 944	progression of muscle weakness
T17	o 959 991	serum creatine kinase activity .